EcoDrugPlus

Glutamate Metabotropic Receptor 3

Ensembl ID : ENSHBUG00000008792
Gene Symbol: GRM3
3 Cross references
215 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSHBUG00000011533
Gene Symbol: GRM4
3 Cross references
207 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSHBUG00000008056
Gene Symbol: GRM4
3 Cross references
196 Possible Orthologues:

Glutamate Metabotropic Receptor 5

Ensembl ID : ENSHBUG00000014063
Gene Symbol: GRM5
3 Cross references
214 Possible Orthologues:

Glutamate Receptor 2-Like

Ensembl ID : ENSHBUG00000008833
Gene Symbol: LOC102312799
3 Cross references
242 Possible Orthologues:

Glutamate Receptor 3-Like

Ensembl ID : ENSHBUG00000003498
Gene Symbol: LOC102305150
3 Cross references
251 Possible Orthologues:

Glutamate Receptor 4

Ensembl ID : ENSHBUG00000012754
Gene Symbol: LOC102292924
3 Cross references
249 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 1

Ensembl ID : ENSHBUG00000005579
Gene Symbol: LOC102302700
3 Cross references
205 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2a-Like

Ensembl ID : ENSHBUG00000018585
Gene Symbol: LOC102295981
2 Cross references
98 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2b-Like

Ensembl ID : ENSHBUG00000004489
Gene Symbol: LOC102304038
3 Cross references
250 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2d-Like

Ensembl ID : ENSHBUG00000013751
Gene Symbol: LOC102306605
2 Cross references
212 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2d-Like

Ensembl ID : ENSHBUG00000019571
Gene Symbol: LOC102307452
2 Cross references
214 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).